Jade Biosciences, INC. (JBIO) — SEC Filings

Overview

Jade Biosciences, INC. (JBIO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1 filed on Dec 22, 2025: Jade Biosciences, Inc. (JBIO) filed an S-1 registration statement on December 22, 2025, for the resale of up to 3,214,286 shares of common stock by a single selling stockholder. These shares were acquired in a private placement (December 2025 PIPE) on December 16, 2025, at a price of $14.00 per shar

Sentiment Summary

Across 40 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 33 neutral, 4 mixed. The dominant filing sentiment for Jade Biosciences, INC. is neutral.

Filing Type Overview

Jade Biosciences, INC. (JBIO) has filed 22 8-K, 1 S-1, 6 10-Q, 2 10-K, 3 SC 13G/A, 1 8-K/A, 3 SC 13D/A, 1 DEF 14A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (40)

• 8-K Filing — 8-K · Apr 22, 2026
• Jade Biosciences Files S-1 for $45M PIPE Resale; Nasdaq Listing Continues — S-1 · Dec 22, 2025 Risk: medium
  Jade Biosciences, Inc. (JBIO) filed an S-1 registration statement on December 22, 2025, for the resale of up to 3,214,286 shares of common stock by a single sel
• 8-K Filing — 8-K · Dec 15, 2025
• JBIO's R&D Surge Drives $95M Loss Amid Autoimmune Pipeline Push — 10-Q · Nov 14, 2025 Risk: high
  Jade Biosciences, Inc. (JBIO) reported a significant increase in its net loss for the nine months ended September 30, 2025, reaching $95.478 million, compared t
• Jade Biosciences Files 8-K with Material Agreements and Disclosures — 8-K · Oct 7, 2025 Risk: medium
  On October 3, 2025, Jade Biosciences, Inc. filed an 8-K report detailing several key events. The company entered into a Material Definitive Agreement, reported
• Jade Biosciences Reports Director and Officer Changes — 8-K · Sep 9, 2025 Risk: low
  On September 5, 2025, Jade Biosciences, Inc. (formerly Aerovate Therapeutics, Inc.) filed an 8-K report detailing changes in its board of directors and executiv
• Jade Biosciences Boosts Cash to $220M Post-Merger, Losses Mount — 10-Q · Aug 13, 2025 Risk: high
  Jade Biosciences, Inc. (JBIO) reported a significant increase in cash and cash equivalents to $220.942 million as of June 30, 2025, up from $69.386 million at D
• Jade Biosciences Announces Board Changes and Material Agreement — 8-K · Jul 1, 2025 Risk: medium
  On June 25, 2025, Jade Biosciences, Inc. announced the departure of two directors, Dr. David Epstein and Mr. David M. R. Gray, and the appointment of two new di
• Jade Biosciences Files 8-K on Asset Disposition — 8-K · May 14, 2025 Risk: medium
  On May 14, 2025, Jade Biosciences, Inc. (formerly Aerovate Therapeutics, Inc.) filed an 8-K report. The filing indicates a completion of acquisition or disposit
• Jade Biosciences Files 8-K with Major Corporate Updates — 8-K · May 1, 2025 Risk: medium
  Jade Biosciences, Inc. (formerly Aerovate Therapeutics, Inc.) filed an 8-K on May 1, 2025, reporting several material events as of April 28, 2025. These include
• Aerovate Therapeutics Files 8-K — 8-K · Apr 29, 2025 Risk: low
  Aerovate Therapeutics, Inc. filed an 8-K on April 29, 2025, reporting information under Regulation FD and including financial statements and exhibits. The compa
• Aerovate Therapeutics Reports Q1 2025 Financials — 10-Q · Apr 25, 2025 Risk: medium
  Aerovate Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $289.85 million and total liabilities of $
• Aerovate Therapeutics Files 8-K Report — 8-K · Apr 23, 2025 Risk: low
  On April 23, 2025, Aerovate Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events." No spec
• Aerovate Therapeutics Files 8-K — 8-K · Apr 21, 2025 Risk: low
  Aerovate Therapeutics, Inc. filed an 8-K on April 21, 2025, reporting on events that occurred on April 16, 2025. The filing indicates matters submitted to a vot
• Aerovate Therapeutics Files 8-K — 8-K · Apr 9, 2025 Risk: medium
  Aerovate Therapeutics, Inc. filed an 8-K on April 9, 2025, reporting an "Other Event." The filing does not contain specific details about the event, dollar amou
• Aerovate Therapeutics Files 8-K — 8-K · Apr 7, 2025 Risk: low
  Aerovate Therapeutics, Inc. filed an 8-K on April 7, 2025, reporting on other events and financial statements. The filing does not contain specific financial fi
• Aerovate Therapeutics Files 2024 10-K — 10-K · Mar 27, 2025 Risk: medium
  Aerovate Therapeutics, Inc. filed its 2024 10-K on March 27, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Aerovate Therapeutics Q3 2024 Financial Update — 10-Q · Nov 12, 2024 Risk: medium
  Aerovate Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $288.7 million and total liabilities o
• Aerovate Therapeutics to be Acquired by InspireMD — 8-K · Oct 31, 2024 Risk: medium
  Aerovate Therapeutics, Inc. announced on October 30, 2024, that it entered into a definitive agreement to be acquired by InspireMD Ltd. for approximately $23.5
• Aerovate Therapeutics Faces Delisting Concerns — 8-K · Oct 17, 2024 Risk: high
  Aerovate Therapeutics, Inc. filed an 8-K on October 17, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's prin
• Aerovate Therapeutics Announces Leadership Changes — 8-K · Oct 10, 2024 Risk: medium
  Aerovate Therapeutics, Inc. announced on October 6, 2024, the departure of its Chief Medical Officer, Dr. Lisa Rojkowska. The company also reported the election
• Aerovate Therapeutics Reports Q2 2024 Results — 10-Q · Aug 12, 2024 Risk: medium
  Aerovate Therapeutics, Inc. reported its financial results for the quarter ended June 30, 2024. The company had total assets of $287.6 million and total liabili
• Aerovate Therapeutics Files 8-K — 8-K · Jul 8, 2024 Risk: low
  On July 8, 2024, Aerovate Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific
• Aerovate Therapeutics Files Amendment on Exit Costs — 8-K/A · Jul 1, 2024 Risk: medium
  Aerovate Therapeutics, Inc. filed an amendment (8-K/A) on July 1, 2024, to its previous report dated June 25, 2024. This amendment pertains to costs associated
• Aerovate Therapeutics Reports Exit Costs — 8-K · Jun 28, 2024 Risk: medium
  On June 25, 2024, Aerovate Therapeutics, Inc. filed an 8-K report detailing costs associated with exit or disposal activities. The company, incorporated in Dela
• RA Capital Amends Stake in Aerovate Therapeutics — SC 13D/A · Jun 20, 2024 Risk: medium
  RA Capital Management, L.P. and its affiliates, including Peter Kolchinsky and Ra Capital Healthcare Fund, L.P., have amended their Schedule 13D filing concerni
• Aerovate Therapeutics Terminates Merger with Hansoh Pharma — 8-K · Jun 17, 2024 Risk: high
  On June 17, 2024, Aerovate Therapeutics, Inc. filed an 8-K report detailing the termination of its merger agreement with Jiangsu Hansoh Pharmaceutical Group Co.
• Aerovate Therapeutics Holds Shareholder Vote — 8-K · Jun 7, 2024 Risk: low
  Aerovate Therapeutics, Inc. filed an 8-K on June 7, 2024, reporting on a meeting held on June 5, 2024, where security holders voted on certain matters. The fili
• Aerovate Therapeutics Files 8-K — 8-K · May 13, 2024 Risk: low
  Aerovate Therapeutics, Inc. filed an 8-K on May 13, 2024, reporting on its results of operations and financial condition. The filing includes financial statemen
• Aerovate Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: low
  Aerovate Therapeutics, Inc. (JBIO) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Aerovate Therapeutics, Inc. filed a 10-Q report for the period
• RA Capital Amends Aerovate Therapeutics Stake — SC 13D/A · Apr 30, 2024 Risk: medium
  RA Capital Management, L.P. and its affiliates, including Peter Kolchinsky and RA Capital Healthcare Fund, L.P., have amended their Schedule 13D filing for Aero
• Aerovate Therapeutics Schedules 2024 Annual Meeting of Stockholders for June 5 — DEF 14A · Apr 26, 2024 Risk: low
  Aerovate Therapeutics, Inc. (JBIO) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Aerovate Therapeutics, Inc. will hold its 2024 Annual Meeti
• Aerovate Therapeutics Files 8-K Report — 8-K · Mar 27, 2024 Risk: low
  On March 27, 2024, Aerovate Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporat
• Aerovate Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 25, 2024 Risk: medium
  Aerovate Therapeutics, Inc. (JBIO) filed a Annual Report (10-K) with the SEC on March 25, 2024. Aerovate Therapeutics, Inc. filed its 2023 Form 10-K on March 25
• Sofinnova Amends Aerovate Therapeutics Stake — SC 13D/A · Feb 20, 2024 Risk: low
  Sofinnova Venture Partners X, L.P. filed an Amendment No. 2 to their Schedule 13D on February 20, 2024, regarding their ownership in Aerovate Therapeutics, Inc.
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• TCG Crossover GP I Takes 7.2% Stake in Aerovate Therapeutics — SC 13G · Feb 9, 2024 Risk: low
  TCG Crossover GP I, LLC, a Delaware-based entity, reported acquiring shared voting and dispositive power over 2,201,274 shares of Aerovate Therapeutics, Inc. co
• Aerovate Therapeutics Files Routine 8-K on Jan 8, 2024 — 8-K · Jan 8, 2024
  Aerovate Therapeutics, Inc. filed an 8-K on January 8, 2024, to disclose information under Regulation FD and provide financial statements and exhibits. This fil

Risk Profile

Risk Assessment: Of JBIO's 34 recent filings, 4 were flagged as high-risk, 17 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Jade Biosciences, INC.'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: N/A
• Net Income: -$95.478M
• EPS: -$0.48
• Debt-to-Equity: N/A
• Cash Position: $50.106M
• Operating Margin: N/A
• Total Assets: $202.450M
• Total Debt: N/A

Key Executives

• Tom Frohlich
• Selling Stockholder
• Dr. David Epstein
• Mr. David M. R. Gray
• Ms. Sarah E. Empey
• Dr. Lisa Rojkowska
• Dr. Jonathan Leff
• Mr. David Epstein
• Peter Kolchinsky
• Dr. James I. Healy
• Dr. Maha Katabi
• Nathalie Auber
• CHEN YU

Industry Context

Jade Biosciences operates in the highly competitive and capital-intensive biopharmaceutical sector, focusing on developing treatments for IgA nephropathy and autoimmune disorders. The industry is characterized by long development cycles, significant regulatory hurdles, and the need for substantial funding to advance drug candidates through clinical trials. Success hinges on innovation, effective clinical trial execution, and securing necessary regulatory approvals.

Top Tags

financials (6) · 10-Q (4) · Autoimmune Diseases (3) · disclosure (3) · regulatory (3) · 8-K (3) · regulatory-filing (3) · pharmaceuticals (3) · sec-filing (3) · Aerovate Therapeutics (3)

Key Numbers

• Shares offered by Selling Stockholder: 3,214,286 — Represents the maximum number of common stock shares available for resale from the December 2025 PIPE.
• Purchase price per share in December 2025 PIPE: $14.00 — The price at which the Selling Stockholder acquired the shares in the private placement.
• Aggregate purchase price of December 2025 PIPE: $45.0 million — Total capital raised by Jade Biosciences from the December 2025 private placement.
• Last reported sale price for JBIO Common Stock: $17.03 — Closing price on The Nasdaq Capital Market as of December 19, 2025.
• Date of Business Combination: April 28, 2025 — When Aerovate Therapeutics, Inc. and Pre-Merger Jade consummated their merger.
• Reverse Stock Split Ratio: 1-for-35 — Effected by Aerovate common stock immediately prior to the merger on April 28, 2025.
• Aggregate amount of Pre-Closing Financing: $334.2 million — Capital raised in connection with the business combination, including convertible notes and accrued interest.
• Date of October 2025 PIPE: October 8, 2025 — When Jade Biosciences completed a private placement raising approximately $135 million.
• Aggregate purchase price of October 2025 PIPE: $135 million — Total capital raised by Jade Biosciences from the October 2025 private placement.
• Shares of Common Stock outstanding: 32,626,730 — Total shares outstanding as of September 30, 2025.
• Net Loss: $95.478M — for the nine months ended September 30, 2025, up from $16.867M in prior period
• Research and Development Expenses: $64.580M — for the nine months ended September 30, 2025, a significant increase from $13.659M
• General and Administrative Expenses: $13.983M — for the nine months ended September 30, 2025, up from $1.896M
• Total Assets: $202.450M — as of September 30, 2025, a substantial increase from $72.799M at December 31, 2024
• Cash and Cash Equivalents: $50.106M — as of September 30, 2025, down from $69.386M at December 31, 2024

Forward-Looking Statements

• {"claim":"Aerovate Therapeutics, Inc. may see increased investor interest due to this significant institutional stake.","entity":"Aerovate Therapeutics, Inc.","targetDate":"Next 3-6 months","confidence":"medium"}

Related Companies

JADE · AVTE · NNDM

Frequently Asked Questions